Menu
Search
|

Menu

Close
X

Progenics Pharmaceuticals Inc PGNX.OQ (NASDAQ Stock Exchange Global Select Market)

5.38 USD
+0.00 (+0.00%)
As of Nov 16
chart
Previous Close 5.38
Open 5.28
Volume 773,873
3m Avg Volume 454,579
Today’s High 5.47
Today’s Low 5.22
52 Week High 9.41
52 Week Low 4.68
Shares Outstanding (mil) 84.54
Market Capitalization (mil) 450.61
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.50 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY18
12
FY17
12
FY16
69
FY15
9
EPS (USD)
FY18
-0.693
FY17
-0.779
FY16
0.156
FY15
-0.561
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
29.34
Price to Sales (TTM)
vs sector
27.69
20.58
Price to Book (MRQ)
vs sector
3.92
4.23
Price to Cash Flow (TTM)
vs sector
--
21.19
Total Debt to Equity (MRQ)
vs sector
40.52
13.84
LT Debt to Equity (MRQ)
vs sector
33.37
9.93
Return on Investment (TTM)
vs sector
-38.81
13.58
Return on Equity (TTM)
vs sector
-67.81
15.11

EXECUTIVE LEADERSHIP

Peter Crowley
Independent Chairman of the Board, Since 2010
Salary: --
Bonus: --
Mark Baker
Chief Executive Officer, Director, Since 2011
Salary: $614,325.00
Bonus: --
Patrick Fabbio
Chief Financial Officer, Senior Vice President, Since 2015
Salary: $375,291.00
Bonus: --
Vivien Wong
Executive Vice President - Development, Since 2016
Salary: $407,459.00
Bonus: --
Benedict Osorio
Senior Vice President - Quality, Since 2018
Salary: $306,634.00
Bonus: $114,988.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

1 World Trade Ctr Fl 47
NEW YORK   NY   10007-0089

Phone: +1646.9752500

Progenics Pharmaceuticals, Inc. is engaged in developing medicines and other products for targeting and treating cancer. The Company's pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools. It also includes commercial product, RELISTOR (methylnaltrexone bromide) for opioid-induced constipation. AZEDRA is a radiotherapeutic product candidate in development as a treatment for malignant and/or recurrent pheochromocytoma and paraganglioma, rare tumors found in the adrenal glands and outside of the adrenal glands, respectively. RELISTOR is a treatment for opioid induced constipation. PyL is a clinical-stage, fluorinated PSMA-targeted Positron Emission Topography (PET) imaging agent for prostate cancer. PSMA TTC is a thorium-227 labeled PSMA-targeted antibody therapeutic.

SPONSORED STORIES